

5.75.016

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2024
<b>Subsection:</b>	Neuromuscular Agents	<b>Original Policy Date:</b>	March 10, 2017
<b>Subject:</b>	Emflaza	<b>Page:</b>	1 of 5

---

**Last Review Date:** March 8, 2024

---

## Emflaza

### Description

#### Emflaza (deflazacort)

---

#### Background

Emflaza (deflazacort) is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD). Specifically, deflazacort is a corticosteroid prodrug, whose active metabolite acts through the glucocorticoid receptor to exert anti-inflammatory and immunosuppressive effects. The precise mechanism by which deflazacort exerts its therapeutic effects in patients with DMD is unknown (1).

#### Regulatory Status

FDA-approved indication: Emflaza is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older (1).

Emflaza can suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic. Corticosteroids reduce resistance to new infections, exacerbate existing infections, increase the risk of disseminated infections, increase the risk of reactivation or exacerbation of latent infections, and mask some signs of infection (1).

All immunizations should be administered according to immunization guidelines prior to starting Emflaza. Live or live-attenuated vaccines should be administered at least 4 to 6 weeks prior to starting Emflaza. Patients on Emflaza may receive concurrent vaccinations, except for live or live-attenuated vaccines (1).

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2024
<b>Subsection:</b>	Neuromuscular Agents	<b>Original Policy Date:</b>	March 10, 2017
<b>Subject:</b>	Emflaza	<b>Page:</b>	2 of 5

---

Monitoring motor changes in patients with DMD requires functional evaluation along with measurement of muscle strength. The need for a reliable outcome measure in diseases of rapid deterioration such as DMD has led to the use of motor functional tests. In a large, multicenter, international clinical trial, the six minute walk test (6MWT) proved to be feasible and highly reliable. Also used are the Motor Function Measure (MFM) and North Star Ambulatory Assessment (NSAA) to help predict loss of ambulation 1 year before its occurrence in order to allow time to adapt rehabilitation, change the patient's environment, and consider acquisition of assistive aids or the use of medications (2-4).

Safety and effectiveness in patients 2 years of age and older have been established (1).

---

## Related policies

Amondys 45, Elevidys, Exondys 51, Viltepso, Vyondys 53

## Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Emflaza may be considered **medically necessary** if the conditions indicated below are met.

Emflaza may be considered **investigational** for all other indications.

## Prior-Approval Requirements

**Age** 2 years of age or older

### Diagnosis

Patient must have the following:

Duchenne muscular dystrophy (DMD)

**AND ALL** of the following:

- Confirmed mutation of the DMD gene
- Serum creatinine kinase activity at least 10 times the upper limit of normal (ULN) prior to initiating treatment

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2024
<b>Subsection:</b>	Neuromuscular Agents	<b>Original Policy Date:</b>	March 10, 2017
<b>Subject:</b>	Emflaza	<b>Page:</b>	3 of 5

---

- c. Inadequate treatment response, intolerance, or contraindication to a 3 month trial of prednisone
- d. Obtain a baseline motor milestone score from **ONE** the following assessments:
  - i. 6-minute walk test (6MWT)
  - ii. North Star Ambulatory Assessment (NSAA)
  - iii. Motor Function Measure (MFM)
- e. **NOT** given concurrently with live vaccinations
- f. Absence of active infection [including tuberculosis and hepatitis B virus (HBV)]
- g. If the patient has a history of hepatitis B (HBV) infection
  - i. Prescriber agrees to monitor for HBV reactivation

---

## Prior – Approval *Renewal* Requirements

**Age** 2 years of age or older

### Diagnosis

Patient must have the following:

Duchenne muscular dystrophy (DMD)

**AND ALL** of the following:

- a. Stabilization OR improvement in motor milestone score from baseline from **ONE** the following assessments:
  - i. 6-minute walk test (6MWT)
  - ii. North Star ambulatory assessment (NSAA)
  - iii. Motor Function Measure (MFM)
- b. **NOT** given concurrently with live vaccinations
- c. Absence of active infection [including tuberculosis and hepatitis B virus (HBV)]
- d. If the patient has a history of hepatitis B (HBV) infection
  - i. Prescriber agrees to monitor for HBV reactivation

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2024
<b>Subsection:</b>	Neuromuscular Agents	<b>Original Policy Date:</b>	March 10, 2017
<b>Subject:</b>	Emflaza	<b>Page:</b>	4 of 5

---

## Pre - PA Allowance

None

## Prior - Approval Limits

**Duration** 6 months

---

## Prior – Approval *Renewal* Limits

**Duration** 12 months

## Rationale

### Summary

Emflaza (deflazacort) is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD). Emflaza acts through the glucocorticoid receptor to exert anti-inflammatory and immunosuppressive effects. The most common adverse reactions are Cushingoid appearance, increase weight, increase appetite, upper respiratory tract infection, cough, pollakiuria, hirsutism, central obesity, and nasopharyngitis. Safety and effectiveness in patients 2 years of age and older have been established (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Emflaza while maintaining optimal therapeutic outcomes.

### References

1. Emflaza [package insert]. South Plainfield, NJ: PTC Therapeutics; June 2021.
2. Mcdonald C, Henricson E, et al. The 6-Minute Walk test and Other Clinical Endpoints in Duchenne Muscular Dystrophy: Reliability, Concurrent Validity, and Minimal Clinically Important Differences from a Multicenter Study. *Muscle Nerve*. 2013 Sep; 48(3): 357–368.
3. Mcdonald C, Henricson E, et al. The 6-Minute Walk test and Other Endpoints in Duchenne Muscular Dystrophy: Longitudinal Natural History Observations Over 48 weeks from a Multicenter Study. *Muscle Nerve*. 2013 Sep; 48(3): 343–356.
4. Vuillerot C, Girardot F, et al. Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the Motor Function Measure. *Developmental Medicine & Child Neurology* 2010, 52: 60–65.

# 5.75.016

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2024
<b>Subsection:</b>	Neuromuscular Agents	<b>Original Policy Date:</b>	March 10, 2017
<b>Subject:</b>	Emflaza	<b>Page:</b>	5 of 5

---

## Policy History

Date	Action
March 2017	Addition to PA
April 2017	Addition of NSAA, MFM and HFMS assessment tools to obtain baseline scores and improvement requirements
June 2017	Annual review
September 2018	Annual review and reference update
June 2019	Reduced age requirement to 2 and older from 5 and older and revised regulatory status section
September 2019	Annual review
June 2020	Annual review
December 2020	Annual review
March 2021	Annual review
April 2021	Removed Hammersmith motor function scale score requirement from initiation and continuation. Revised renewal motor function score to stabilization or improvement instead of point requirement per FEP.
June 2021	Annual editorial review and reference update
March 2022	Annual review and reference update
March 2023	Annual review. Changed policy number to 5.75.016
September 2023	Annual review
December 2023	Annual review
March 2024	Annual review

## Keywords

---

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 8, 2024 and is effective on April 1, 2024.**